ETV1, 4 and 5: An oncogenic subfamily of ETS transcription factors

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 1, 2012, Pages 1-12

  Oh, Sangphil ^a   Shin, Sook ^a   Janknecht, Ralf ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Chromosomal translocation; ETS; Posttranslational modification; Transcription factor

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; PROTEIN ETV1; PROTEIN ETV4; PROTEIN ETV5; TRANSCRIPTION FACTOR PEA3; UNCLASSIFIED DRUG;

BRANCHING MORPHOGENESIS; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; EWING SARCOMA; FERTILITY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MOTOR COORDINATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; TUMOR CELL;

ADENOVIRUS E1A PROTEINS; AMINO ACID SEQUENCE; DNA-BINDING PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ETS; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 84859038513     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.02.002     Document Type: Review

References (180)

1. Hsu T., Trojanowska M., Watson D.K. Ets proteins in biological control and cancer. J. Cell. Biochem. 2004, 91:896-903.
2. Sharrocks A.D. The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2001, 2:827-837.
3. Hollenhorst P.C., McIntosh L.P., Graves B.J. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu. Rev. Biochem. 2011, 80:437-471.
4. De Haro L., Janknecht R. Cloning of the murine ER71 gene (Etsrp71) and initial characterization of its promoter. Genomics 2005, 85:493-502.
5. Hollenhorst P.C., Jones D.A., Graves B.J. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res. 2004, 32:5693-5702.
6. Xin J.H., Cowie A., Lachance P., Hassell J.A. Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells. Genes Dev. 1992, 6:481-496.
7. Higashino F., Yoshida K., Fujinaga Y., Kamio K., Fujinaga K. Isolation of a cDNA encoding the adenovirus E1A enhancer binding protein: a new human member of the ets oncogene family. Nucleic Acids Res. 1993, 21:547-553.
8. Brown T.A., McKnight S.L. Specificities of protein-protein and protein-DNA interaction of GABP alpha and two newly defined ets-related proteins. Genes Dev. 1992, 6:2502-2512.
9. Monte D., Baert J.L., Defossez P.A., de Launoit Y., Stehelin D. Molecular cloning and characterization of human ERM, a new member of the Ets family closely related to mouse PEA3 and ER81 transcription factors. Oncogene 1994, 9:1397-1406.
10. Janknecht R. Analysis of the ERK-stimulated ETS transcription factor ER81. Mol. Cell. Biol. 1996, 16:1550-1556.
11. Laget M.P., Defossez P.A., Albagli O., Baert J.L., Dewitte F., Stehelin D., de Launoit Y. Two functionally distinct domains responsible for transactivation by the Ets family member ERM. Oncogene 1996, 12:1325-1336.
12. Bojovic B.B., Hassell J.A. The PEA3 Ets transcription factor comprises multiple domains that regulate transactivation and DNA binding. J. Biol. Chem. 2001, 276:4509-4521.
13. Wei G.H., Badis G., Berger M.F., Kivioja T., Palin K., Enge M., Bonke M., Jolma A., Varjosalo M., Gehrke A.R., Yan J., Talukder S., Turunen M., Taipale M., Stunnenberg H.G., Ukkonen E., Hughes T.R., Bulyk M.L., Taipale J. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J. 2010, 29:2147-2160.
14. Brown L.A., Amores A., Schilling T.F., Jowett T., Baert J.L., de Launoit Y., Sharrocks A.D. Molecular characterization of the zebrafish PEA3 ETS-domain transcription factor. Oncogene 1998, 17:93-104.
15. Greenall A., Willingham N., Cheung E., Boam D.S., Sharrocks A.D. DNA binding by the ETS-domain transcription factor PEA3 is regulated by intramolecular and intermolecular protein.protein interactions. J. Biol. Chem. 2001, 276:16207-16215.
16. Bosc D.G., Janknecht R. Regulation of HER2/Neu promoter activity by the ETS transcription factor, ER81. J. Cell. Biochem. 2002, 86:174-183.
17. Dowdy S.C., Mariani A., Janknecht R. HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J. Biol. Chem. 2003, 278:44377-44384.
18. Baert J.L., Beaudoin C., Coutte L., de Launoit Y. ERM transactivation is up-regulated by the repression of DNA binding after the PKA phosphorylation of a consensus site at the edge of the ETS domain. J. Biol. Chem. 2002, 277:1002-1012.
19. Wu J., Janknecht R. Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A. J. Biol. Chem. 2002, 277:42669-42679.
20. Goel A., Janknecht R. Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu. Mol. Cell. Biol. 2003, 23:6243-6254.
21. Chotteau-Lelievre A., Desbiens X., Pelczar H., Defossez P.A., de Launoit Y. Differential expression patterns of the PEA3 group transcription factors through murine embryonic development. Oncogene 1997, 15:937-952.
22. Chotteau-Lelievre A., Dolle P., Peronne V., Coutte L., de Launoit Y., Desbiens X. Expression patterns of the Ets transcription factors from the PEA3 group during early stages of mouse development. Mech. Dev. 2001, 108:191-195.
23. Chotteau-Lelievre A., Montesano R., Soriano J., Soulie P., Desbiens X., de Launoit Y. PEA3 transcription factors are expressed in tissues undergoing branching morphogenesis and promote formation of duct-like structures by mammary epithelial cells in vitro. Dev. Biol. 2003, 259:241-257.
24. Lu B.C., Cebrian C., Chi X., Kuure S., Kuo R., Bates C.M., Arber S., Hassell J., MacNeil L., Hoshi M., Jain S., Asai N., Takahashi M., Schmidt-Ott K.M., Barasch J., D'Agati V., Costantini F. Etv4 and Etv5 are required downstream of GDNF and Ret for kidney branching morphogenesis. Nat. Genet. 2009, 41:1295-1302.
25. Mao J., McGlinn E., Huang P., Tabin C.J., McMahon A.P. Fgf-dependent Etv4/5 activity is required for posterior restriction of Sonic Hedgehog and promoting outgrowth of the vertebrate limb. Dev. Cell 2009, 16:600-606.
26. Zhang Z., Verheyden J.M., Hassell J.A., Sun X. FGF-regulated Etv genes are essential for repressing Shh expression in mouse limb buds. Dev. Cell 2009, 16:607-613.
27. Arber S., Ladle D.R., Lin J.H., Frank E., Jessell T.M. ETS gene Er81 controls the formation of functional connections between group Ia sensory afferents and motor neurons. Cell 2000, 101:485-498.
28. Kucera J., Cooney W., Que A., Szeder V., Stancz-Szeder H., Walro J. Formation of supernumerary muscle spindles at the expense of Golgi tendon organs in ER81-deficient mice. Dev. Dyn. 2002, 223:389-401.
29. Sedy J., Tseng S., Walro J.M., Grim M., Kucera J. ETS transcription factor ER81 is required for the Pacinian corpuscle development. Dev. Dyn. 2006, 235:1081-1089.
30. Laing M.A., Coonrod S., Hinton B.T., Downie J.W., Tozer R., Rudnicki M.A., Hassell J.A. Male sexual dysfunction in mice bearing targeted mutant alleles of the PEA3 ets gene. Mol. Cell. Biol. 2000, 20:9337-9345.
31. Livet J., Sigrist M., Stroebel S., De Paola V., Price S.R., Henderson C.E., Jessell T.M., Arber S. ETS gene Pea3 controls the central position and terminal arborization of specific motor neuron pools. Neuron 2002, 35:877-892.
32. Ladle D.R., Frank E. The role of the ETS gene PEA3 in the development of motor and sensory neurons. Physiol. Behav. 2002, 77:571-576.
33. Chen C., Ouyang W., Grigura V., Zhou Q., Carnes K., Lim H., Zhao G.Q., Arber S., Kurpios N., Murphy T.L., Cheng A.M., Hassell J.A., Chandrashekar V., Hofmann M.C., Hess R.A., Murphy K.M. ERM is required for transcriptional control of the spermatogonial stem cell niche. Nature 2005, 436:1030-1034.
34. Schlesser H.N., Simon L., Hofmann M.C., Murphy K.M., Murphy T., Hess R.A., Cooke P.S. Effects of ETV5 (ets variant gene 5) on testis and body growth, time course of spermatogonial stem cell loss, and fertility in mice. Biol. Reprod. 2008, 78:483-489.
35. Eo J., Shin H., Kwon S., Song H., Murphy K.M., Lim J.H. Complex ovarian defects lead to infertility in Etv5-/- female mice. Mol. Hum. Reprod. 2011, 17:568-576.
36. Trimble M.S., Xin J.H., Guy C.T., Muller W.J., Hassell J.A. PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas. Oncogene 1993, 8:3037-3042.
37. Shepherd T.G., Kockeritz L., Szrajber M.R., Muller W.J., Hassell J.A. The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr. Biol. 2001, 11:1739-1748.
38. Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 2003, 284:99-110.
39. Hall P.S., Cameron D.A. Current perspective-trastuzumab. Eur. J. Cancer 2009, 45:12-18.
40. Benz C.C., O'Hagan R.C., Richter B., Scott G.K., Chang C.H., Xiong X., Chew K., Ljung B.M., Edgerton S., Thor A., Hassell J.A. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 1997, 15:1513-1525.
41. Davidson B., Goldberg I., Tell L., Vigdorchik S., Baekelandt M., Berner A., Kristensen G.B., Reich R., Kopolovic J. The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin. Exp. Metastasis 2004, 21:191-199.
42. Fleming F.J., Myers E., Kelly G., Crotty T.B., McDermott E.W., O'Higgins N.J., Hill A.D., Young L.S. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J. Clin. Pathol. 2004, 57:1069-1074.
43. Myers E., Hill A.D., Kelly G., McDermott E.W., O'Higgins N.J., Young L.S. A positive role for PEA3 in HER2-mediated breast tumour progression. Br. J. Cancer 2006, 95:1404-1409.
44. Wang Y., Wang L., Chen Y., Li L., Yang X., Li B., Song S., Yang L., Hao Y., Yang J. ER81 expression in breast cancers and hyperplasia. Pathology Res. Int. 2011, 2011:980513.
45. Chotteau-Lelievre A., Revillion F., Lhotellier V., Hornez L., Desbiens X., Cabaret V., de Launoit Y., Peyrat J.P. Prognostic value of ERM gene expression in human primary breast cancers. Clin. Cancer Res. 2004, 10:7297-7303.
46. Span P.N., Manders P., Heuvel J.J., Beex L.V., Sweep C.G. E1AF expression levels are not associated with prognosis in human breast cancer. Breast Cancer Res. Treat. 2003, 79:129-131.
47. Xia W.Y., Lien H.C., Wang S.C., Pan Y., Sahin A., Kuo Y.H., Chang K.J., Zhou X., Wang H., Yu Z., Hortobagyi G., Shi D.R., Hung M.C. Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer. Breast Cancer Res. Treat. 2006, 98:295-301.
48. Baker R., Kent C.V., Silbermann R.A., Hassell J.A., Young L.J., Howe L.R. Pea3 transcription factors and wnt1-induced mouse mammary neoplasia. PLoS One 2010, 5:e8854.
49. Shin S., Bosc D.G., Ingle J.N., Spelsberg T.C., Janknecht R. Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors. J. Cell. Biochem. 2008, 105:866-874.
50. Firlej V., Ladam F., Brysbaert G., Dumont P., Fuks F., de Launoit Y., Benecke A., Chotteau-Lelievre A. Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or Erm-dependent transcription. J. Cell Sci. 2008, 121:3393-3402.
51. O'Hagan R.C., Hassell J.A. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. Oncogene 1998, 16:301-310.
52. Bosc D.G., Goueli B.S., Janknecht R. HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 2001, 20:6215-6224.
53. Ishida S., Higashino F., Aoyagi M., Takahashi A., Suzuki T., Shindoh M., Fujinaga K., Yoshida K. Genomic structure and promoter activity of the E1AF gene, a member of the ETS oncogene family. Biochem. Biophys. Res. Commun. 2006, 339:325-330.
54. Xing X., Wang S.C., Xia W., Zou Y., Shao R., Kwong K.Y., Yu Z., Zhang S., Miller S., Huang L., Hung M.C. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat. Med. 2000, 6:189-195.
55. Janknecht R., Monte D., Baert J.L., de Launoit Y. The ETS-related transcription factor ERM is a nuclear target of signaling cascades involving MAPK and PKA. Oncogene 1996, 13:1745-1754.
56. O'Hagan R.C., Tozer R.G., Symons M., McCormick F., Hassell J.A. The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades. Oncogene 1996, 13:1323-1333.
57. Janknecht R. Regulation of the ER81 transcription factor and its coactivators by mitogen- and stress-activated protein kinase 1 (MSK1). Oncogene 2003, 22:746-755.
58. Xu J., Wu R.C., O'Malley B.W. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat. Rev. Cancer 2009, 9:615-630.
59. Goel A., Janknecht R. Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J. Biol. Chem. 2004, 279:14909-14916.
60. Qin L., Liao L., Redmond A., Young L., Yuan Y., Chen H., O'Malley B.W., Xu J. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol. Cell. Biol. 2008, 28:5937-5950.
61. Higashino F., Yoshida K., Noumi T., Seiki M., Fujinaga K. Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters. Oncogene 1995, 10:1461-1463.
62. Crawford H.C., Fingleton B., Gustavson M.D., Kurpios N., Wagenaar R.A., Hassell J.A., Matrisian L.M. The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol. Cell. Biol. 2001, 21:1370-1383.
63. Brinckerhoff C.E., Matrisian L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 2002, 3:207-214.
64. Kaya M., Yoshida K., Higashino F., Mitaka T., Ishii S., Fujinaga K. A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene 1996, 12:221-227.
65. Goueli B.S., Janknecht R. Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol. Cell. Biol. 2004, 24:25-35.
66. Vageli D., Ioannou M.G., Koukoulis G.K. Transcriptional activation of hTERT in breast carcinomas by the Her2-ER81-related pathway. Oncol. Res. 2009, 17:413-423.
67. Hiyama E., Hiyama K. Telomerase as tumor marker. Cancer Lett. 2003, 194:221-233.
68. Janknecht R. On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett. 2004, 564:9-13.
69. Howe L.R., Crawford H.C., Subbaramaiah K., Hassell J.A., Dannenberg A.J., Brown A.M. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J. Biol. Chem. 2001, 276:20108-20115.
70. Subbaramaiah K., Norton L., Gerald W., Dannenberg A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 2002, 277:18649-18657.
71. Liu Y., Borchert G.L., Phang J.M. Polyoma enhancer activator 3, an ets transcription factor, mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells. J. Biol. Chem. 2004, 279:18694-18700.
72. Singh-Ranger G., Salhab M., Mokbel K. The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res. Treat. 2008, 109:189-198.
73. Galang C.K., Muller W.J., Foos G., Oshima R.G., Hauser C.A. Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J. Biol. Chem. 2004, 279:11281-11292.
74. Netzer S., Leenders F., Dumont P., Baert J.L., de Launoit Y. Ectopic expression of the ets transcription factor ER81 in transgenic mouse mammary gland enhances both urokinase plasminogen activator and stromelysin-1 transcription. Transgenic Res. 2002, 11:123-131.
75. Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 2005, 363:1-14.
76. Zucman J., Melot T., Desmaze C., Ghysdael J., Plougastel B., Peter M., Zucker J.M., Triche T.J., Sheer D., Turc-Carel C., Ambros P., Combaret V., Lenoir G., Aurias A., Thomas G., Delattre O. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 1993, 12:4481-4487.
77. Peter M., Couturier J., Pacquement H., Michon J., Thomas G., Magdelenat H., Delattre O. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997, 14:1159-1164.
78. Jeon I.S., Davis J.N., Braun B.S., Sublett J.E., Roussel M.F., Denny C.T., Shapiro D.N. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995, 10:1229-1234.
79. Urano F., Umezawa A., Hong W., Kikuchi H., Hata J. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Biochem. Biophys. Res. Commun. 1996, 219:608-612.
80. Lessnick S.L., Braun B.S., Denny C.T., May W.A. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene 1995, 10:423-431.
81. Rossow K.L., Janknecht R. The Ewing's sarcoma gene product functions as a transcriptional activator. Cancer Res. 2001, 61:2690-2695.
82. Toomey E.C., Schiffman J.D., Lessnick S.L. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene 2010, 29:4504-4516.
83. Gangwal K., Sankar S., Hollenhorst P.C., Kinsey M., Haroldsen S.C., Shah A.A., Boucher K.M., Watkins W.S., Jorde L.B., Graves B.J., Lessnick S.L. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10149-10154.
84. Guillon N., Tirode F., Boeva V., Zynovyev A., Barillot E., Delattre O. The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS One 2009, 4:e4932.
85. Bernstein M., Kovar H., Paulussen M., Randall R.L., Schuck A., Teot L.A., Juergens H. Ewing's sarcoma family of tumors: current management. Oncologist 2006, 11:503-519.
86. Fuchs B., Inwards C.Y., Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin. Cancer Res. 2004, 10:1344-1353.
87. Dalal S., Berry A.M., Cullinane C.J., Mangham D.C., Grimer R., Lewis I.J., Johnston C., Laurence V., Burchill S.A. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin. Cancer Res. 2005, 11:2364-2378.
88. Guan H., Zhou Z., Wang H., Jia S.F., Liu W., Kleinerman E.S. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin. Cancer Res. 2005, 11:2662-2669.
89. Stewart K.S., Kleinerman E.S. Tumor vessel development and expansion in Ewing's sarcoma: a review of the vasculogenesis process and clinical trials with vascular-targeting agents. Sarcoma 2011, 2011:165837.
90. Kawamura-Saito M., Yamazaki Y., Kaneko K., Kawaguchi N., Kanda H., Mukai H., Gotoh T., Motoi T., Fukayama M., Aburatani H., Takizawa T., Nakamura T. Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum. Mol. Genet. 2006, 15:2125-2137.
91. Dissanayake K., Toth R., Blakey J., Olsson O., Campbell D.G., Prescott A.R., MacKintosh C. ERK/p90(RSK)/14-3-3 signalling has an impact on expression of PEA3 Ets transcription factors via the transcriptional repressor capicua. Biochem. J. 2011, 433:515-525.
92. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
93. Ramirez M.L., Keane T.E., Evans C.P. Managing prostate cancer: the role of hormone therapy. Can. J. Urol. 2007, 14(Suppl. 1):10-18.
94. Shand R.L., Gelmann E.P. Molecular biology of prostate-cancer pathogenesis. Curr. Opin. Urol. 2006, 16:123-131.
95. Attard G., Cooper C.S., de Bono J.S. Steroid hormone receptors in prostate cancer: a hard habit to break?. Cancer Cell 2009, 16:458-462.
96. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
97. Tomlins S.A., Mehra R., Rhodes D.R., Smith L.R., Roulston D., Helgeson B.E., Cao X., Wei J.T., Rubin M.A., Shah R.B., Chinnaiyan A.M. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006, 66:3396-3400.
98. Helgeson B.E., Tomlins S.A., Shah N., Laxman B., Cao Q., Prensner J.R., Cao X., Singla N., Montie J.E., Varambally S., Mehra R., Chinnaiyan A.M. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 2008, 68:73-80.
99. Lin B., Ferguson C., White J.T., Wang S., Vessella R., True L.D., Hood L., Nelson P.S. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 1999, 59:4180-4184.
100. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008, 8:497-511.
101. Clark J.P., Cooper C.S. ETS gene fusions in prostate cancer. Nat. Rev. Urol. 2009, 6:429-439.
102. Lin C., Yang L., Tanasa B., Hutt K., Ju B.G., Ohgi K., Zhang J., Rose D.W., Fu X.D., Glass C.K., Rosenfeld M.G. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009, 139:1069-1083.
103. Mani R.S., Tomlins S.A., Callahan K., Ghosh A., Nyati M.K., Varambally S., Palanisamy N., Chinnaiyan A.M. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009, 326:1230.
104. Haffner M.C., Aryee M.J., Toubaji A., Esopi D.M., Albadine R., Gurel B., Isaacs W.B., Bova G.S., Liu W., Xu J., Meeker A.K., Netto G., De Marzo A.M., Nelson W.G., Yegnasubramanian S. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 2010, 42:668-675.
105. Tomlins S.A., Laxman B., Dhanasekaran S.M., Helgeson B.E., Cao X., Morris D.S., Menon A., Jing X., Cao Q., Han B., Yu J., Wang L., Montie J.E., Rubin M.A., Pienta K.J., Roulston D., Shah R.B., Varambally S., Mehra R., Chinnaiyan A.M. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448:595-599.
106. Klezovitch O., Risk M., Coleman I., Lucas J.M., Null M., True L.D., Nelson P.S., Vasioukhin V. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2105-2110.
107. Tomlins S.A., Laxman B., Varambally S., Cao X., Yu J., Helgeson B.E., Cao Q., Prensner J.R., Rubin M.A., Shah R.B., Mehra R., Chinnaiyan A.M. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10:177-188.
108. Shin S., Kim T.D., Jin F., van Deursen J.M., Dehm S.M., Tindall D.J., Grande J.P., Munz J.M., Vasmatzis G., Janknecht R. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res. 2009, 69:8102-8110.
109. Carver B.S., Tran J., Gopalan A., Chen Z., Shaikh S., Carracedo A., Alimonti A., Nardella C., Varmeh S., Scardino P.T., Cordon-Cardo C., Gerald W., Pandolfi P.P. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 2009, 41:619-624.
110. King J.C., Xu J., Wongvipat J., Hieronymus H., Carver B.S., Leung D.H., Taylor B.S., Sander C., Cardiff R.D., Couto S.S., Gerald W.L., Sawyers C.L. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 2009, 41:524-526.
111. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010, 24:1967-2000.
112. Yoshimoto M., Joshua A.M., Cunha I.W., Coudry R.A., Fonseca F.P., Ludkovski O., Zielenska M., Soares F.A., Squire J.A. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod. Pathol. 2008, 21:1451-1460.
113. Reid A.H., Attard G., Ambroisine L., Fisher G., Kovacs G., Brewer D., Clark J., Flohr P., Edwards S., Berney D.M., Foster C.S., Fletcher A., Gerald W.L., Moller H., Reuter V.E., Scardino P.T., Cuzick J., de Bono J.S., Cooper C.S. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br. J. Cancer 2010, 102:678-684.
114. Abate-Shen C., Shen M.M., Gelmann E. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 2008, 76:717-727.
115. Cai C., Hsieh C.L., Omwancha J., Zheng Z., Chen S.Y., Baert J.L., Shemshedini L. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol. Endocrinol. 2007, 21:1835-1846.
116. Sun C., Dobi A., Mohamed A., Li H., Thangapazham R.L., Furusato B., Shaheduzzaman S., Tan S.H., Vaidyanathan G., Whitman E., Hawksworth D.J., Chen Y., Nau M., Patel V., Vahey M., Gutkind J.S., Sreenath T., Petrovics G., Sesterhenn I.A., McLeod D.G., Srivastava S. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008, 27:5348-5353.
117. Wang J., Cai Y., Yu W., Ren C., Spencer D.M., Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 2008, 68:8516-8524.
118. Hermans K.G., van der Korput H.A., van Marion R., van de Wijngaart D.J., Ziel-van der Made A., Dits N.F., Boormans J.L., van der Kwast T.H., van Dekken H., Bangma C.H., Korsten H., Kraaij R., Jenster G., Trapman J. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res. 2008, 68:7541-7549.
119. Hollenhorst P.C., Paul L., Ferris M.W., Graves B.J. The ETS gene ETV4 is required for anchorage-independent growth and a cell proliferation gene expression program in PC3 prostate cells. Genes Cancer 2011, 1:1044-1052.
120. Smith R., Owen L.A., Trem D.J., Wong J.S., Whangbo J.S., Golub T.R., Lessnick S.L. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006, 9:405-416.
121. Hollenhorst P.C., Ferris M.W., Hull M.A., Chae H., Kim S., Graves B.J. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev. 2011, 25:2147-2157.
122. Massie C.E., Adryan B., Barbosa-Morais N.L., Lynch A.G., Tran M.G., Neal D.E., Mills I.G. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep. 2007, 8:871-878.
123. Yu J., Yu J., Mani R.S., Cao Q., Brenner C.J., Cao X., Wang X., Wu L., Li J., Hu M., Gong Y., Cheng H., Laxman B., Vellaichamy A., Shankar S., Li Y., Dhanasekaran S.M., Morey R., Barrette T., Lonigro R.J., Tomlins S.A., Varambally S., Qin Z.S., Chinnaiyan A.M. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010, 17:443-454.
124. Schneikert J., Peterziel H., Defossez P.A., Klocker H., Launoit Y., Cato A.C. Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J. Biol. Chem. 1996, 271:23907-23913.
125. Zong Y., Xin L., Goldstein A.S., Lawson D.A., Teitell M.A., Witte O.N. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12465-12470.
126. Cai C., Hsieh C.L., Shemshedini L. c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer. Mol. Cancer Res. 2007, 5:725-735.
127. Nakae K., Nakajima K., Inazawa J., Kitaoka T., Hirano T. ERM, a PEA3 subfamily of Ets transcription factors, can cooperate with c-Jun. J. Biol. Chem. 1995, 270:23795-23800.
128. El-Tanani M., Platt-Higgins A., Rudland P.S., Campbell F.C. Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J. Biol. Chem. 2004, 279:20794-20806.
129. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., Antipin Y., Mitsiades N., Landers T., Dolgalev I., Major J.E., Wilson M., Socci N.D., Lash A.E., Heguy A., Eastham J.A., Scher H.I., Reuter V.E., Scardino P.T., Sander C., Sawyers C.L., Gerald W.L. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
130. Palanisamy N., Ateeq B., Kalyana-Sundaram S., Pflueger D., Ramnarayanan K., Shankar S., Han B., Cao Q., Cao X., Suleman K., Kumar-Sinha C., Dhanasekaran S.M., Chen Y.B., Esgueva R., Banerjee S., LaFargue C.J., Siddiqui J., Demichelis F., Moeller P., Bismar T.A., Kuefer R., Fullen D.R., Johnson T.M., Greenson J.K., Giordano T.J., Tan P., Tomlins S.A., Varambally S., Rubin M.A., Maher C.A., Chinnaiyan A.M. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 2010, 16:793-798.
131. Signoretti S., Montironi R., Manola J., Altimari A., Tam C., Bubley G., Balk S., Thomas G., Kaplan I., Hlatky L., Hahnfeldt P., Kantoff P., Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 2000, 92:1918-1925.
132. Nishio Y., Yamada Y., Kokubo H., Nakamura K., Aoki S., Taki T., Honda N., Nakagawa A., Saga S., Hara K. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 2006, 68:110-115.
133. Takahashi A., Higashino F., Aoyagi M., Yoshida K., Itoh M., Kobayashi M., Totsuka Y., Kohgo T., Shindoh M. E1AF degradation by a ubiquitin-proteasome pathway. Biochem. Biophys. Res. Commun. 2005, 327:575-580.
134. Baert J.L., Beaudoin C., Monte D., Degerny C., Mauen S., de Launoit Y. The 26S proteasome system degrades the ERM transcription factor and regulates its transcription-enhancing activity. Oncogene 2007, 26:415-424.
135. Yi C., Deng X.W. COP1-from plant photomorphogenesis to mammalian tumorigenesis. Trends Cell Biol. 2005, 15:618-625.
136. Baert J.L., Monte D., Verreman K., Degerny C., Coutte L., de Launoit Y. The E3 ubiquitin ligase complex component COP1 regulates PEA3 group member stability and transcriptional activity. Oncogene 2010, 29:1810-1820.
137. Vitari A.C., Leong K.G., Newton K., Yee C., O'Rourke K., Liu J., Phu L., Vij R., Ferrando R., Couto S.S., Mohan S., Pandita A., Hongo J.A., Arnott D., Wertz I.E., Gao W.Q., French D.M., Dixit V.M. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature 2011, 474:403-406.
138. Guo B., Sharrocks A.D. Extracellular signal-regulated kinase mitogen-activated protein kinase signaling initiates a dynamic interplay between sumoylation and ubiquitination to regulate the activity of the transcriptional activator PEA3. Mol. Cell. Biol. 2009, 29:3204-3218.
139. Hay R.T. SUMO: a history of modification. Mol. Cell 2005, 18:1-12.
140. Degerny C., Monte D., Beaudoin C., Jaffray E., Portois L., Hay R.T., de Launoit Y., Baert J.L. SUMO modification of the Ets-related transcription factor ERM inhibits its transcriptional activity. J. Biol. Chem. 2005, 280:24330-24338.
141. Nishida T., Terashima M., Fukami K., Yamada Y. Repression of E1AF transcriptional activity by sumoylation and PIASy. Biochem. Biophys. Res. Commun. 2007, 360:226-232.
142. Bojovic B.B., Hassell J.A. The transactivation function of the Pea3 subfamily Ets transcription factors is regulated by sumoylation. DNA Cell Biol. 2008, 27:289-305.
143. Geiss-Friedlander R., Melchior F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 2007, 8:947-956.
144. Degerny C., de Launoit Y., Baert J.L. ERM transcription factor contains an inhibitory domain which functions in sumoylation-dependent manner. Biochim. Biophys. Acta 2008, 1779:183-194.
145. Gareau J.R., Lima C.D. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 2010, 11:861-871.
146. Bawa-Khalfe T., Cheng J., Wang Z., Yeh E.T. Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J. Biol. Chem. 2007, 282:37341-37349.
147. Bawa-Khalfe T., Cheng J., Lin S.H., Ittmann M.M., Yeh E.T. SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J. Biol. Chem. 2010, 285:25859-25866.
148. Janknecht R. The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. Histol. Histopathol. 2002, 17:657-668.
149. Papoutsopoulou S., Janknecht R. Phosphorylation of ETS transcription factor ER81 in a complex with its coactivators CREB-binding protein and p300. Mol. Cell. Biol. 2000, 20:7300-7310.
150. Heemers H.V., Tindall D.J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 2007, 28:778-808.
151. Guo B., Panagiotaki N., Warwood S., Sharrocks A.D. Dynamic modification of the ETS transcription factor PEA3 by sumoylation and p300-mediated acetylation. Nucleic Acids Res. 2011, 39:6403-6413.
152. Debes J.D., Sebo T.J., Lohse C.M., Murphy L.M., Haugen D.A., Tindall D.J. p300 in prostate cancer proliferation and progression. Cancer Res. 2003, 63:7638-7640.
153. Horiuchi S., Yamamoto H., Min Y., Adachi Y., Itoh F., Imai K. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J. Pathol. 2003, 200:568-576.
154. Boedefeld W.M., Soong R., Weiss H., Diasio R.B., Urist M.M., Bland K.I., Heslin M.J. E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7. Mol. Carcinog. 2005, 43:13-17.
155. Nosho K., Yoshida M., Yamamoto H., Taniguchi H., Adachi Y., Mikami M., Hinoda Y., Imai K. Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 2005, 26:892-899.
156. Moss A.C., Lawlor G., Murray D., Tighe D., Madden S.F., Mulligan A.M., Keane C.O., Brady H.R., Doran P.P., MacMathuna P. ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion. Biochem. Biophys. Res. Commun. 2006, 345:216-221.
157. Liu H.Y., Zhou B., Wang L., Li Y., Zhou Z.G., Sun X.F., Xu B., Zeng Y.J., Song J.M., Luo H.Z., Yang L. Association of E1AF mRNA expression with tumor progression and matrilysin in human rectal cancer. Oncology 2007, 73:384-388.
158. Jung Y., Lee S., Choi H.S., Kim S.N., Lee E., Shin Y., Seo J., Kim B., Jung Y., Kim W.K., Chun H.K., Lee W.Y., Kim J. Clinical validation of colorectal cancer biomarkers identified from bioinformatics analysis of public expression data. Clin. Cancer Res. 2011, 17:700-709.
159. Deves C., Renck D., Garicochea B., da Silva V.D., Giulianni Lopes T., Fillman H., Fillman L., Lunardini S., Basso L.A., Santos D.S., Batista E.L. Analysis of select members of the E26 (ETS) transcription factors family in colorectal cancer. Virchows Arch. 2011, 458:421-430.
160. Yamamoto H., Horiuchi S., Adachi Y., Taniguchi H., Nosho K., Min Y., Imai K. Expression of ets-related transcriptional factor E1AF is associated with tumor progression and over-expression of matrilysin in human gastric cancer. Carcinogenesis 2004, 25:325-332.
161. Keld R., Guo B., Downey P., Cummins R., Gulmann C., Ang Y.S., Sharrocks A.D. PEA3/ETV4-related transcription factors coupled with active ERK signalling are associated with poor prognosis in gastric adenocarcinoma. Br. J. Cancer 2011, 105:124-130.
162. Keld R., Guo B., Downey P., Gulmann C., Ang Y.S., Sharrocks A.D. The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma. Mol. Cancer 2010, 9:313.
163. Yuen H.F., McCrudden C.M., Chan K.K., Chan Y.P., Wong M.L., Chan K.Y., Khoo U.S., Law S., Srivastava G., Lappin T.R., Chan K.W., El-Tanani M. The role of Pea3 group transcription factors in esophageal squamous cell carcinoma. Am. J. Pathol. 2011, 179:992-1003.
164. Davidson B., Goldberg I., Gotlieb W.H., Kopolovic J., Ben-Baruch G., Reich R. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin. Cancer Res. 2003, 9:1412-1419.
165. Planaguma J., Abal M., Gil-Moreno A., Diaz-Fuertes M., Monge M., Garcia A., Baro T., Xercavins J., Reventos J., Alameda F. Up-regulation of ERM/ETV5 correlates with the degree of myometrial infiltration in endometrioid endometrial carcinoma. J. Pathol. 2005, 207:422-429.
166. Monge M., Colas E., Doll A., Gonzalez M., Gil-Moreno A., Planaguma J., Quiles M., Arbos M.A., Garcia A., Castellvi J., Llaurado M., Rigau M., Alazzouzi H., Xercavins J., Alameda F., Reventos J., Abal M. ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res. 2007, 67:6753-6759.
167. Hida K., Shindoh M., Yoshida K., Kudoh A., Furaoka K., Kohgo T., Fujinaga K., Totsuka Y. Expression of E1AF, an ets-family transcription factor, is correlated with the invasive phenotype of oral squamous cell carcinoma. Oral Oncol. 1997, 33:426-430.
168. Hanzawa M., Shindoh M., Higashino F., Yasuda M., Inoue N., Hida K., Ono M., Kohgo T., Nakamura M., Notani K., Fukuda H., Totsuka Y., Yoshida K., Fujinaga K. Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis 2000, 21:1079-1085.
169. Hiroumi H., Dosaka-Akita H., Yoshida K., Shindoh M., Ohbuchi T., Fujinaga K., Nishimura M. Expression of E1AF/PEA3, an Ets-related transcription factor in human non-small-cell lung cancers: its relevance in cell motility and invasion. Int. J. Cancer 2001, 93:786-791.
170. Job B., Bernheim A., Beau-Faller M., Camilleri-Broet S., Girard P., Hofman P., Mazieres J., Toujani S., Lacroix L., Laffaire J., Dessen P., Fouret P. Genomic aberrations in lung adenocarcinoma in never smokers. PLoS One 2010, 5:e15145.
171. Jane-Valbuena J., Widlund H.R., Perner S., Johnson L.A., Dibner A.C., Lin W.M., Baker A.C., Nazarian R.M., Vijayendran K.G., Sellers W.R., Hahn W.C., Duncan L.M., Rubin M.A., Fisher D.E., Garraway L.A. An oncogenic role for ETV1 in melanoma. Cancer Res. 2010, 70:2075-2084.
172. Pierotti M.A., Tamborini E., Negri T., Pricl S., Pilotti S. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat. Rev. Clin. Oncol. 2011, 8:161-170.
173. Chi P., Chen Y., Zhang L., Guo X., Wongvipat J., Shamu T., Fletcher J.A., Dewell S., Maki R.G., Zheng D., Antonescu C.R., Allis C.D., Sawyers C.L. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 2010, 467:849-853.
174. Arkenau H.T., Kefford R., Long G.V. Targeting BRAF for patients with melanoma. Br. J. Cancer 2011, 104:392-398.
175. Garraway L.A., Widlund H.R., Rubin M.A., Getz G., Berger A.J., Ramaswamy S., Beroukhim R., Milner D.A., Granter S.R., Du J., Lee C., Wagner S.N., Li C., Golub T.R., Rimm D.L., Meyerson M.L., Fisher D.E., Sellers W.R. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
176. Brenner J.C., Ateeq B., Li Y., Yocum A.K., Cao Q., Asangani I.A., Patel S., Wang X., Liang H., Yu J., Palanisamy N., Siddiqui J., Yan W., Cao X., Mehra R., Sabolch A., Basrur V., Lonigro R.J., Yang J., Tomlins S.A., Maher C.A., Elenitoba-Johnson K.S., Hussain M., Navone N.M., Pienta K.J., Varambally S., Feng F.Y., Chinnaiyan A.M. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011, 19:664-678.
177. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., Taylor M.J., Johns C., Chicas A., Mulloy J.C., Kogan S.C., Brown P., Valent P., Bradner J.E., Lowe S.W., Vakoc C.R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.
178. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.I., Robson S.C., Chung C.W., Hopf C., Savitski M.M., Huthmacher C., Gudgin E., Lugo D., Beinke S., Chapman T.D., Roberts E.J., Soden P.E., Auger K.R., Mirguet O., Doehner K., Delwel R., Burnett A.K., Jeffrey P., Drewes G., Lee K., Huntly B.J., Kouzarides T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
179. Erkizan H.V., Kong Y., Merchant M., Schlottmann S., Barber-Rotenberg J.S., Yuan L., Abaan O.D., Chou T.H., Dakshanamurthy S., Brown M.L., Uren A., Toretsky J.A. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat. Med. 2009, 15:750-756.
180. Rahim S., Beauchamp E.M., Kong Y., Brown M.L., Toretsky J.A., Uren A. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS One 2011, 6:e19343.